Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PEN 110

Drug Profile

PEN 110

Alternative Names: INACTINE; INACTINE™ Pathogen Inactivation red blood cell product; INACTINE™ Pathogen Reduction System for Red Cells; PEN110

Latest Information Update: 05 Jul 2005

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Panacos Pharmaceuticals Inc
  • Class Polyamines
  • Mechanism of Action DNA cross linking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Graft-versus-host disease; Infections

Most Recent Events

  • 05 Jul 2005 The INACTINE system is available for licensing (http://www.vitechnologies.com)
  • 05 Jul 2005 Discontinued - Phase-III for Infections in USA (Extracorporeal)
  • 05 Jul 2005 Discontinued - Preclinical for Graft-versus-host disease in USA (Extracorporeal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top